Community Series in Novel CNS targeting Molecules, Methods, and Therapeutics in Multiple Sclerosis: Vol. II

This Research Topic is the second volume of the “Novel CNS targeting Molecules, Methods, and Therapeutics in Multiple Sclerosis” Community Series. Please see Volume I here.

Multiple sclerosis (MS) is a chronic autoimmune and neurodegenerative disease of the central nervous system (CNS), affecting nearly one million individuals in the United States and an estimated three million people worldwide. MS is characterized by neuroinflammation, demyelination, and neuronal degeneration/loss with profound heterogeneity in disease presentation, trajectory, and treatment efficacy. It is the most prevalent neurological condition that affects young adults, hits during the years when productivity is at its highest, and has a severely detrimental impact on patients, their families, and the healthcare system.

Current disease-modifying therapies are highly effective in slowing the progression of relapsing-remitting MS by preventing symptomatic relapses, which are characterized by white matter lesions caused by inflammatory CNS-infiltrating immune cells. However, these therapies are frequently associated with an increased risk of infections and show a weak effect for infiltrated immune cell functions in the CNS. Thus, drugs that target the CNS and/or show less infectious risk are urgently needed and could provide a promising future therapeutic option for MS.

The purpose of this Research Topic to convey the current progression of the pathogenic alterations in the CNS under MS conditions, which would be therapeutic target and diagnosis. In addition, we also collect the novel drugs, which target CNS alterations in MS. We welcome submissions of Original Research, Perspective, Clinical Trial and Review articles on human and/or animal studies. Suggested Sub-Topics for Submission:

• Autoimmune Mechanisms in Neuroinflammation and Demyelination

• Targeting Autoimmune Pathways for CNS Protection

• Novel Immune-Modulating Therapies with Reduced Infection Risk

• Early Diagnostic Markers for Autoimmune Activity in MS.

• Development of diagnostic tools and biomarkers to detect early autoimmune activity in MS.

• Comprehensive Approaches to Managing Autoimmunity in MS.

By exploring these cutting-edge topics, we aim to drive forward a comprehensive understanding of MS autoimmunity and foster the development of novel, targeted treatments and diagnostic approaches that improve patient outcomes and reduce adverse effects.

Let’s advance MS research together and work towards innovative therapeutic solutions that can profoundly impact the lives of those affected by this challenging disease. We look forward to your valuable contributions.